In esophageal cancer, Gal‐3 can promote cancer progression through activation of the AKT/ERK pathway [42], while Yao et al. [43] reported that, in pancreatic cancer, inhibition of Gal‐3 blocked the AKT/FOXO3 signaling pathway and subsequently suppressed cancer progression. Here, LGALS3 is linked to cancer.